Source comparison
Melanotan-2 vs PDE5 Inhibitors vs PT-141: Mechanism Comparison
Melanotan-2 (MT-2) Melanocortin receptor agonist. Central nervous system activation of erectile pathways MC3R, MC4R in hypothalamus 2–6 hours (subcutaneous) 48–72 hours per dose 72–80% response rate in vascular/diabetic ED Most effective for organic ED unrespo
This comparison does not assign a generated winner or score.
- Melanotan-2 (MT-2)
- Melanocortin receptor agonist. Central nervous system activation of erectile pathways
- MC3R, MC4R in hypothalamus
- 2–6 hours (subcutaneous)
- 48–72 hours per dose
- 72–80% response rate in vascular/diabetic ED
- Most effective for organic ED unresponsive to PDE5 inhibitors; nausea limits tolerability above 2mg doses
- Sildenafil (Viagra)
- PDE5 enzyme inhibitor. Peripheral smooth muscle relaxation in corpus cavernosum
- PDE5 in penile vascular tissue
- 30–60 minutes (oral)
- 4–6 hours
- 40–50% response in severe vascular ED
- First-line therapy; requires intact nitric oxide pathway; less effective when nerve damage or severe atherosclerosis present
- PT-141 (Bremelanotide)
- Melanocortin receptor agonist. Identical mechanism to MT-2 but modified structure
- MC4R in paraventricular nucleus
- 45–90 minutes (intranasal)
- 6–12 hours
- 65–70% in women with hypoactive desire; 60% in men with psychogenic ED
- FDA-approved specifically for female sexual dysfunction; lower nausea rates than MT-2 but shorter duration
- Tadalafil (Cialis)
- PDE5 enzyme inhibitor. Longer half-life than sildenafil
- PDE5 in penile and pulmonary vascular tissue
- 60–120 minutes (oral)
- 24–36 hours
- 45–55% in diabetic/vascular ED
- Daily low-dose option available; same mechanism as sildenafil with extended window